



# THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

## **Supplementary Material**

**Article Title:** Trends in Medication Prescribing in Patients With PTSD From 2009 to 2018: A National Veterans Administration Study

**Author(s):** Nicholas Holder, PhD; Anne Woods, MS; Thomas C. Neylan, MD; Shira Maguen, PhD; Karen H. Seal, MD, MPH; Nancy Bernardy, PhD; Ilse Wiechers, MD; Annie Ryder, BA; Ana-Marie Urbiet, MSW; and Beth E. Cohen, MD

**DOI Number:** <https://doi.org/10.4088/JCP.20m13522>

### **List of Supplementary Material for the article**

1. [Table 1](#) Gender Differences in Pharmacotherapy Among Veterans Diagnosed with PTSD by Year (2009-2018)
2. [Table 2](#) Race Differences in Pharmacotherapy Among Veterans Diagnosed with PTSD by Year (2009-2018)
3. [Table 3](#) Ethnicity Differences in Pharmacotherapy Among Veterans Diagnosed with PTSD by Year (2009-2018)
4. [Table 4](#) Service Era Differences in Pharmacotherapy Among Veterans Diagnosed with PTSD by Year (2009-2018)
5. [Table 5](#) Gender Differences in New Prescriptions Among Veterans Diagnosed with PTSD by Year (2009-2018)
6. [Table 6](#) Race Differences in New Prescriptions Among Veterans Diagnosed with PTSD by Year (2009-2018)
7. [Table 7](#) Ethnicity Differences in New Prescriptions Among Veterans Diagnosed with PTSD by Year (2009-2018)
8. [Table 8](#) Service Era Differences in New Prescriptions Among Veterans Diagnosed with PTSD by Year (2009-2018)

### **Disclaimer**

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table 1. *Gender Differences in Pharmacotherapy Among Veterans Diagnosed with PTSD by Year (2009-2018)*

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
Any PTSD Medication <sup>a</sup>	M	66.9%	65.4%	64.0%	62.6%	61.3%	60.3%	59.8%	58.9%	58.0%	57.3%	-9.6%
	F	69.7%	68.5%	67.4%	66.2%	65.4%	64.9%	65.5%	65.0%	64.5%	64.5%	-5.2%
SSRI or SNRI	M	51.5%	50.0%	48.6%	46.8%	45.7%	45.0%	45.1%	44.8%	44.5%	44.2%	-7.3%
	F	58.3%	57.0%	55.7%	54.3%	53.7%	53.7%	54.9%	54.9%	54.8%	54.9%	-3.4%
SSRI	M	46.5%	44.9%	43.2%	41.0%	39.3%	38.3%	37.5%	36.0%	34.7%	33.7%	-12.8%
	F	49.4%	48.0%	46.2%	44.3%	43.0%	42.6%	42.6%	41.3%	40.0%	39.4%	-10.0%
SNRI	M	6.8%	6.9%	7.2%	7.8%	8.3%	8.6%	9.9%	11.3%	12.2%	12.9%	6.1%
	F	12.7%	12.6%	13.0%	13.6%	14.3%	14.8%	16.5%	18.2%	19.2%	19.9%	7.2%
Atypical Antipsychotic	M	12.5%	11.2%	10.0%	8.9%	8.2%	7.7%	7.2%	6.9%	6.9%	6.9%	-5.6%
	F	11.0%	10.1%	9.2%	8.4%	7.9%	7.6%	7.3%	7.2%	7.3%	7.6%	-3.4%
Tricyclic Antidepressant	M	5.2%	4.8%	4.4%	4.1%	4.0%	3.9%	3.8%	3.5%	3.3%	3.1%	-2.1%
	F	7.8%	7.5%	7.0%	6.8%	6.6%	6.4%	6.1%	5.9%	5.6%	5.4%	-2.4%
Mirtazapine	M	8.4%	8.3%	8.3%	8.3%	8.2%	8.2%	8.2%	8.0%	7.8%	7.7%	-0.7%
	F	5.8%	5.8%	5.7%	5.7%	5.7%	6.0%	6.1%	6.0%	5.9%	5.7%	-0.1%
Prazosin	M	7.8%	9.0%	10.2%	11.5%	12.6%	13.7%	14.6%	14.8%	14.8%	14.3%	6.5%
	F	5.3%	6.6%	7.4%	8.9%	10.0%	11.3%	12.3%	12.6%	12.6%	12.2%	6.9%
Trazodone	M	21.5%	20.7%	19.9%	19.3%	19.0%	18.9%	18.7%	18.1%	17.4%	17.0%	-4.5%
	F	20.7%	19.9%	19.6%	19.2%	18.9%	19.2%	19.5%	18.9%	18.1%	18.1%	-2.6%
Non-Benzodiazepine Hypnotic	M	11.0%	11.5%	11.7%	11.4%	10.4%	9.3%	8.5%	7.5%	6.6%	5.8%	-5.2%
	F	14.5%	15.2%	15.1%	14.8%	13.2%	11.5%	10.7%	9.5%	8.5%	7.4%	-7.1%
Benzodiazepine	M	24.2%	22.9%	21.8%	20.6%	19.1%	17.0%	14.7%	12.2%	10.0%	8.4%	-15.8%
	F	28.5%	27.3%	26.4%	25.2%	23.8%	21.3%	18.7%	15.6%	13.3%	11.3%	-17.2%

*Abbreviations.* F, Female; M, Male; PTSD, Posttraumatic Stress Disorder; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective-serotonin reuptake inhibitor.

Supplementary Table 2. *Race Differences in Pharmacotherapy Among Veterans Diagnosed with PTSD by Year (2009-2018)*

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
Any PTSD Medication	AI/AN	63.2%	62.0%	61.6%	60.1%	58.9%	57.3%	57.3%	56.5%	55.5%	55.0%	-8.2%
	Asian	57.3%	56.9%	56.6%	55.8%	55.6%	57.0%	57.0%	57.0%	56.6%	57.1%	-0.2%
	Black	66.4%	65.2%	63.8%	62.6%	61.4%	60.8%	60.7%	60.1%	59.5%	58.9%	-7.5%
	NH/OPI	65.1%	64.3%	62.6%	62.0%	60.0%	59.7%	59.6%	58.9%	57.8%	56.9%	-8.2%
	Unknown	60.8%	58.9%	57.3%	56.1%	54.9%	54.2%	54.0%	53.5%	53.1%	53.5%	-7.3%
	White	68.0%	66.5%	65.1%	63.6%	62.4%	61.3%	60.8%	59.9%	59.0%	58.3%	-9.7%
SSRI or SNRI	AI/AN	48.8%	47.6%	47.0%	45.2%	44.0%	43.3%	43.4%	42.8%	42.6%	42.3%	-6.5%
	Asian	42.1%	41.5%	40.8%	40.4%	40.4%	42.5%	43.7%	44.1%	44.3%	45.4%	3.3%
	Black	49.0%	47.9%	46.6%	45.1%	44.1%	44.0%	44.4%	44.6%	44.6%	44.6%	-4.4%
	NH/OPI	50.0%	48.3%	47.4%	46.6%	45.2%	45.0%	45.7%	45.8%	45.1%	44.6%	-5.4%
	Unknown	46.1%	44.5%	43.1%	41.3%	40.3%	40.0%	40.4%	40.5%	40.6%	41.6%	-4.5%
	White	53.4%	51.8%	50.3%	48.7%	47.5%	46.8%	46.9%	46.6%	46.3%	46.0%	-7.4%
SSRI	AI/AN	44.1%	43.0%	42.1%	39.7%	37.8%	36.3%	35.5%	33.6%	32.5%	31.6%	-12.5%
	Asian	39.5%	38.3%	37.7%	36.6%	35.8%	37.2%	37.4%	36.3%	35.4%	35.8%	-3.7%
	Black	46.0%	44.7%	43.0%	41.0%	39.5%	39.0%	38.4%	37.4%	36.1%	35.2%	-10.8%
	NH/OPI	45.7%	43.8%	42.5%	41.5%	39.5%	39.0%	38.5%	37.3%	35.8%	34.5%	-11.2%
	Unknown	41.8%	40.3%	38.5%	36.5%	35.0%	34.5%	33.9%	32.9%	32.2%	32.3%	-9.5%
	White	47.5%	45.8%	44.1%	41.8%	40.1%	39.0%	38.2%	36.6%	35.3%	34.3%	-13.2%
SNRI	AI/AN	6.6%	6.5%	6.7%	7.5%	7.9%	8.9%	10.5%	11.7%	12.7%	13.3%	6.7%
	Asian	4.0%	4.2%	4.6%	5.6%	6.4%	7.4%	8.9%	10.5%	11.5%	12.2%	8.2%
	Black	4.3%	4.5%	4.9%	5.6%	6.1%	6.6%	8.1%	9.6%	10.8%	11.7%	7.4%
	NH/OPI	6.2%	6.0%	6.3%	7.0%	7.5%	7.9%	9.5%	10.9%	11.9%	12.4%	6.2%
	Unknown	5.6%	5.5%	5.8%	6.2%	6.7%	7.0%	8.3%	9.7%	10.6%	11.5%	5.9%
	White	8.2%	8.1%	8.5%	9.1%	9.7%	10.0%	11.4%	12.9%	13.8%	14.5%	6.3%
Atypical Antipsychotic	AI/AN	11.1%	9.6%	8.8%	8.0%	7.4%	6.9%	6.7%	6.2%	6.1%	6.5%	-4.6%
	Asian	9.4%	9.2%	7.8%	6.5%	6.1%	6.0%	5.9%	6.4%	6.9%	7.3%	-2.1%
	Black	13.0%	11.5%	10.2%	9.0%	8.2%	7.9%	7.5%	7.3%	7.3%	7.5%	-5.5%

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
	NH/OPI	11.5%	10.6%	9.7%	8.7%	7.8%	7.0%	6.8%	6.4%	6.5%	6.6%	-4.9%
	Unknown	8.9%	8.0%	7.1%	6.3%	5.8%	5.6%	5.3%	5.2%	5.3%	5.7%	-3.2%
	White	12.7%	11.4%	10.2%	9.0%	8.3%	7.8%	7.3%	7.0%	6.9%	6.9%	-5.8%
Tricyclic Antidepressant	AI/AN	5.5%	5.4%	4.9%	4.4%	4.4%	4.4%	4.5%	3.9%	3.6%	3.6%	-1.9%
	Asian	4.1%	4.3%	4.1%	3.9%	4.0%	3.7%	3.5%	3.9%	3.7%	3.5%	-0.6%
	Black	5.5%	5.0%	4.6%	4.4%	4.2%	4.1%	4.1%	3.9%	3.7%	3.5%	-2.0%
	NH/OPI	5.2%	4.7%	4.3%	4.4%	4.1%	4.3%	4.0%	3.8%	3.7%	3.4%	-1.8%
	Unknown	4.4%	3.9%	3.7%	3.5%	3.4%	3.4%	3.2%	3.2%	3.0%	3.0%	-1.4%
	White	5.4%	5.0%	4.6%	4.4%	4.3%	4.2%	4.0%	3.8%	3.5%	3.4%	-2.0%
Mirtazapine	AI/AN	6.6%	6.2%	6.2%	6.4%	6.4%	6.5%	7.0%	6.8%	6.7%	6.4%	-0.2%
	Asian	6.8%	6.8%	6.8%	7.2%	6.8%	7.0%	7.2%	7.3%	7.0%	7.2%	0.4%
	Black	9.6%	9.8%	9.9%	9.7%	9.6%	9.6%	9.7%	9.5%	9.1%	9.0%	-0.6%
	NH/OPI	7.5%	7.3%	7.3%	7.4%	6.8%	7.3%	7.2%	7.1%	6.4%	6.5%	-1.0%
	Unknown	7.0%	6.9%	6.8%	6.7%	6.5%	6.5%	6.7%	6.5%	6.4%	6.5%	-0.5%
	White	8.0%	7.9%	7.9%	7.8%	7.8%	7.7%	7.7%	7.5%	7.3%	7.1%	-0.9%
Prazosin	AI/AN	9.7%	11.3%	12.1%	13.4%	14.3%	14.8%	15.2%	15.4%	15.0%	14.5%	4.8%
	Asian	7.6%	10.2%	11.3%	13.1%	14.4%	16.2%	16.8%	17.0%	17.5%	17.4%	9.8%
	Black	7.0%	8.4%	9.9%	11.5%	13.1%	14.8%	16.3%	17.0%	17.4%	17.2%	10.2%
	NH/OPI	7.9%	10.2%	12.1%	13.1%	14.1%	15.5%	16.6%	17.0%	17.2%	16.5%	8.6%
	Unknown	6.6%	7.5%	8.5%	9.9%	10.9%	11.9%	12.9%	13.3%	13.6%	14.1%	7.5%
	White	7.8%	8.9%	10.0%	11.3%	12.3%	13.2%	13.8%	13.8%	13.6%	13.0%	5.2%
Trazodone	AI/AN	19.9%	18.7%	18.4%	18.2%	17.8%	17.7%	17.2%	16.7%	16.3%	16.0%	-3.9%
	Asian	15.9%	15.4%	15.7%	15.8%	15.8%	16.3%	16.2%	15.9%	15.8%	14.8%	-1.1%
	Black	25.5%	24.8%	23.9%	22.9%	22.4%	22.4%	22.2%	21.2%	20.1%	19.6%	-5.9%
	NH/OPI	20.8%	19.6%	18.9%	18.7%	17.9%	17.9%	17.3%	16.9%	16.4%	16.2%	-4.6%
	Unknown	18.0%	17.2%	16.7%	16.5%	16.3%	16.3%	16.2%	15.8%	15.3%	15.3%	-2.7%
	White	20.8%	20.0%	19.3%	18.7%	18.4%	18.3%	18.1%	17.6%	16.9%	16.6%	-4.2%

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
Non- Benzodiazepine Hypnotics	AI/AN	11.3%	12.1%	12.6%	12.1%	10.9%	9.5%	8.8%	7.5%	6.5%	5.8%	-5.5%
	Asian	11.9%	12.6%	12.9%	13.0%	12.3%	11.2%	10.1%	8.8%	8.1%	7.4%	-4.5%
	Black	9.1%	9.6%	9.9%	9.8%	8.9%	8.0%	7.2%	6.5%	5.7%	5.1%	-4.0%
	NH/OPI	11.5%	12.1%	12.8%	12.0%	11.4%	10.2%	9.4%	8.2%	7.4%	6.7%	-4.8%
	Unknown	9.7%	10.3%	10.5%	10.4%	9.5%	8.5%	7.8%	7.0%	6.1%	5.5%	-4.2%
	White	11.9%	12.4%	12.5%	12.2%	11.1%	10.0%	9.1%	8.1%	7.1%	6.3%	-5.6%
Benzodiazepines	AI/AN	22.5%	20.8%	20.1%	19.4%	18.2%	16.5%	14.0%	11.5%	9.3%	7.8%	-14.7%
	Asian	17.1%	16.1%	15.9%	15.0%	13.7%	12.6%	11.0%	9.1%	7.9%	7.1%	-10.0%
	Black	15.1%	14.2%	13.3%	12.5%	11.4%	10.0%	8.7%	7.1%	5.8%	4.9%	-10.2%
	NH/OPI	21.8%	20.8%	19.7%	19.0%	17.4%	15.6%	13.4%	11.2%	8.8%	7.4%	-14.4%
	Unknown	22.5%	21.4%	20.3%	19.0%	17.5%	15.6%	13.6%	11.4%	9.4%	7.5%	-15.0%
	White	27.2%	25.7%	24.7%	23.5%	21.9%	19.7%	17.1%	14.4%	11.9%	10.1%	-17.1%

*Abbreviations.* AI/AN, American Indian or Alaska Native; NH/OPI, Native Hawaiian or Other Pacific Islander; PTSD, Posttraumatic Stress Disorder; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective-serotonin reuptake inhibitor.

Supplementary Table 3. *Ethnicity Differences in Pharmacotherapy Among Veterans Diagnosed with PTSD by Year (2009-2018)*

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
Any PTSD Medication	H/L	65.8%	64.4%	63.3%	62.1%	61.2%	60.6%	60.3%	59.6%	59.0%	58.2%	-7.6%
	Not H/L	67.5%	66.0%	64.6%	63.1%	61.9%	60.9%	60.5%	59.6%	58.8%	58.2%	-9.3%
SSRI or SNRI	H/L	51.2%	49.8%	48.7%	46.9%	46.5%	46.2%	46.4%	46.5%	46.4%	46.2%	-5.0%
	Not H/L	52.3%	50.7%	49.3%	47.6%	46.5%	45.9%	46.1%	45.8%	45.6%	45.4%	-6.9%
SSRI	H/L	47.1%	45.4%	44.0%	41.9%	40.7%	39.9%	39.3%	38.1%	36.9%	35.8%	-11.3%
	Not H/L	47.0%	45.3%	43.6%	41.4%	39.7%	38.7%	37.9%	36.5%	35.2%	34.3%	-12.7%
SNRI	H/L	5.7%	5.9%	6.4%	6.8%	7.7%	8.2%	9.7%	11.2%	12.3%	13.1%	7.4%
	Not H/L	7.4%	7.4%	7.7%	8.3%	8.9%	9.3%	10.6%	12.1%	13.1%	13.7%	6.3%
Atypical Antipsychotic	H/L	12.1%	10.7%	9.4%	8.2%	7.7%	7.2%	6.6%	6.5%	6.5%	6.5%	-5.6%
	Not H/L	12.6%	11.3%	10.1%	9.0%	8.3%	7.8%	7.3%	7.1%	7.0%	7.1%	-5.6%
Tricyclic Antidepressant	H/L	4.6%	4.1%	3.9%	3.7%	3.8%	3.8%	3.6%	3.5%	3.3%	3.3%	-1.3%
	Not H/L	5.4%	5.0%	4.6%	4.4%	4.3%	4.2%	4.0%	3.8%	3.6%	3.4%	-2.0%
Mirtazapine	H/L	7.6%	7.2%	7.5%	7.3%	7.4%	7.4%	7.7%	7.7%	7.5%	7.1%	-0.5%
	Not H/L	8.3%	8.3%	8.3%	8.2%	8.1%	8.1%	8.1%	7.9%	7.7%	7.5%	-0.8%
Prazosin	H/L	8.7%	10.0%	11.3%	13.0%	14.4%	15.7%	16.8%	16.9%	16.9%	16.5%	7.8%
	Not H/L	7.6%	8.8%	9.9%	11.2%	12.3%	13.4%	14.2%	14.4%	14.4%	13.9%	6.3%
Trazodone	H/L	21.3%	20.3%	19.7%	19.4%	19.0%	19.1%	18.9%	18.4%	17.6%	16.9%	-4.4%
	Not H/L	21.6%	20.8%	20.0%	19.4%	19.1%	19.0%	18.8%	18.2%	17.5%	17.2%	-4.4%
Non-Benzodiazepine Hypnotics	H/L	10.6%	12.1%	12.5%	12.8%	11.7%	10.3%	9.4%	8.4%	7.5%	6.8%	-3.8%
	Not H/L	11.4%	11.8%	11.9%	11.6%	10.6%	9.5%	8.6%	7.7%	6.7%	5.9%	-5.5%
Benzodiazepines	H/L	22.4%	21.1%	20.2%	19.2%	18.0%	16.0%	13.6%	11.0%	8.8%	7.4%	-15.0%
	Not H/L	24.7%	23.4%	22.3%	21.1%	19.6%	17.6%	15.2%	12.7%	10.5%	8.9%	-15.8%

*Abbreviations.* H/L, Hispanic or Latino; PTSD, Posttraumatic Stress Disorder; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective-serotonin reuptake inhibitor.

Supplementary Table 4. *Service Era Differences in Pharmacotherapy Among Veterans Diagnosed with PTSD by Year (2009-2018)*

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
Any PTSD Medication	OEF/OIF/OND	63.2%	61.9%	60.8%	60.0%	59.5%	59.1%	59.1%	58.3%	57.3%	56.3%	-6.9%
	Not OEF/OIF/OND	67.9%	66.5%	65.2%	63.7%	62.3%	61.3%	60.8%	60.0%	59.3%	58.8%	-9.1%
SSRI or SNRI	OEF/OIF/OND	49.0%	47.3%	46.2%	45.3%	45.1%	45.3%	46.1%	45.9%	45.5%	44.9%	-4.1%
	Not OEF/OIF/OND	52.6%	51.2%	49.8%	48.0%	46.7%	45.9%	45.9%	45.7%	45.6%	45.5%	-7.1%
SSRI	OEF/OIF/OND	45.0%	43.0%	41.4%	39.8%	38.9%	38.5%	38.3%	36.9%	35.6%	34.5%	-10.5%
	Not OEF/OIF/OND	47.1%	45.6%	44.0%	41.7%	39.9%	38.7%	37.8%	36.4%	35.1%	34.3%	-12.8%
SNRI	OEF/OIF/OND	6.2%	6.5%	7.1%	7.8%	8.7%	9.3%	10.8%	12.1%	12.9%	13.4%	7.2%
	Not OEF/OIF/OND	7.4%	7.4%	7.7%	8.3%	8.8%	9.1%	10.4%	11.9%	13.0%	13.7%	6.3%
Atypical Antipsychotic	OEF/OIF/OND	11.5%	10.5%	9.4%	8.5%	8.0%	7.7%	7.2%	7.0%	7.1%	7.1%	-4.4%
	Not OEF/OIF/OND	12.6%	11.3%	10.1%	8.9%	8.2%	7.7%	7.2%	6.9%	6.8%	6.9%	-5.7%
Tricyclic Antidepressant	OEF/OIF/OND	5.0%	4.6%	4.3%	4.1%	4.3%	4.2%	4.0%	3.8%	3.6%	3.4%	-1.6%
	Not OEF/OIF/OND	5.4%	5.0%	4.6%	4.4%	4.2%	4.1%	4.0%	3.7%	3.5%	3.4%	-2.0%
Mirtazapine	OEF/OIF/OND	7.3%	7.2%	7.1%	7.1%	7.0%	7.2%	7.3%	7.0%	6.6%	6.3%	-1.0%
	Not OEF/OIF/OND	8.4%	8.4%	8.4%	8.4%	8.3%	8.3%	8.3%	8.2%	8.1%	8.0%	-0.4%
Prazosin	OEF/OIF/OND	10.3%	12.1%	13.5%	15.1%	16.5%	17.9%	18.7%	18.5%	17.9%	16.9%	6.6%
	Not OEF/OIF/OND	7.1%	8.0%	9.0%	10.2%	11.0%	11.9%	12.6%	12.9%	13.1%	12.8%	5.7%
Trazodone	OEF/OIF/OND	20.0%	18.9%	18.0%	17.7%	17.7%	17.9%	17.7%	16.8%	15.8%	15.4%	-4.6%
	Not OEF/OIF/OND	21.8%	21.0%	20.4%	19.8%	19.4%	19.4%	19.2%	18.8%	18.2%	17.9%	-3.9%
Non-Benzodiazepine Hypnotics	OEF/OIF/OND	15.1%	15.2%	14.9%	14.1%	12.6%	11.0%	9.9%	8.7%	7.7%	6.7%	-8.4%
	Not OEF/OIF/OND	10.4%	10.9%	11.1%	10.9%	10.0%	9.0%	8.2%	7.3%	6.4%	5.7%	-4.7%
Benzodiazepines	OEF/OIF/OND	17.2%	16.6%	16.2%	15.4%	14.5%	12.8%	10.9%	8.9%	7.3%	6.3%	-10.9%
	Not OEF/OIF/OND	26.1%	24.7%	23.7%	22.6%	21.1%	19.1%	16.7%	14.1%	11.7%	9.8%	-16.3%

*Abbreviations.* OEF/OIF/OND, Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn; PTSD, Posttraumatic Stress Disorder; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective-serotonin reuptake inhibitor.

Supplementary Table 5. *Gender Differences in New Prescriptions Among Veterans Diagnosed with PTSD by Year (2009-2018)*

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
SSRI or SNRI	M	11.6%	11.3%	11.9%	12.3%	11.2%	11.2%	12.1%	12.1%	11.9%	11.8%	0.2%
	F	17.0%	16.2%	16.9%	16.8%	16.5%	16.8%	18.0%	18.2%	18.0%	17.9%	0.9%
SSRI	M	9.9%	9.6%	10.0%	10.3%	9.1%	9.0%	9.1%	8.5%	8.3%	8.1%	-1.8%
	F	13.6%	12.9%	13.4%	13.1%	12.6%	12.9%	13.0%	12.7%	12.3%	12.3%	-1.3%
SNRI	M	2.1%	2.1%	2.3%	2.5%	2.5%	2.6%	3.6%	4.2%	4.2%	4.2%	2.1%
	F	4.2%	4.1%	4.4%	4.6%	4.8%	4.9%	6.1%	6.8%	6.8%	6.7%	2.5%
Atypical Antipsychotic	M	4.4%	3.8%	3.2%	2.8%	2.6%	2.5%	2.4%	2.4%	2.5%	2.5%	-1.9%
	F	4.8%	4.2%	3.7%	3.4%	3.1%	3.1%	3.0%	3.0%	3.1%	3.3%	-1.5%
Tricyclic Antidepressant	M	1.7%	1.7%	1.5%	1.5%	1.5%	1.5%	1.4%	1.3%	1.2%	1.2%	-0.5%
	F	3.3%	3.1%	3.0%	3.0%	2.8%	2.8%	2.6%	2.5%	2.5%	2.5%	-0.8%
Mirtazapine	M	2.8%	2.9%	2.9%	2.9%	2.8%	2.9%	2.9%	2.8%	2.7%	2.7%	-0.1%
	F	2.5%	2.7%	2.6%	2.5%	2.5%	2.8%	2.7%	2.7%	2.7%	2.6%	0.1%
Prazosin	M	3.0%	3.4%	3.8%	4.3%	4.4%	4.7%	4.8%	4.7%	4.6%	4.1%	1.1%
	F	2.3%	3.1%	3.3%	3.9%	4.2%	4.6%	4.8%	4.9%	4.7%	4.4%	2.1%
Trazodone	M	5.7%	5.8%	5.6%	5.6%	5.6%	5.7%	5.6%	5.4%	5.1%	5.0%	-0.7%
	F	7.1%	6.9%	7.0%	6.9%	6.9%	7.1%	7.0%	6.7%	6.5%	6.7%	-0.4%
Non-Benzodiazepine Hypnotics	M	2.6%	2.7%	2.7%	2.6%	2.2%	2.1%	1.9%	1.6%	1.4%	1.3%	-1.3%
	F	3.9%	4.2%	4.0%	3.9%	3.4%	3.2%	2.9%	2.4%	2.3%	2.0%	-1.9%
Benzodiazepines	M	4.9%	4.9%	4.7%	4.5%	4.1%	3.6%	3.0%	2.5%	2.1%	1.8%	-3.1%
	F	7.8%	7.7%	7.9%	7.5%	6.9%	6.2%	5.3%	4.4%	4.0%	3.4%	-4.4%

*Abbreviations.* F, Female; M, Male; PTSD, Posttraumatic Stress Disorder; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective-serotonin reuptake inhibitor.



Supplementary Table 6. *Race Differences in New Prescriptions Among Veterans Diagnosed with PTSD by Year (2009-2018)*

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
SSRI or SNRI	AI/AN	12.3%	11.7%	12.4%	12.9%	11.3%	11.7%	13.1%	12.6%	13.0%	12.7%	0.4%
	Asian	9.8%	10.5%	10.6%	11.5%	11.0%	11.2%	12.9%	12.9%	12.7%	13.0%	3.2%
	Black	13.3%	13.3%	13.6%	13.9%	12.9%	13.2%	14.1%	14.2%	14.1%	14.2%	0.9%
	NH/OPI	11.8%	11.3%	12.0%	12.8%	12.0%	11.8%	13.0%	12.9%	12.7%	12.7%	0.9%
	Unknown	9.7%	9.7%	10.0%	10.6%	9.8%	9.7%	10.4%	10.8%	10.8%	10.4%	0.7%
	White	11.9%	11.4%	12.0%	12.5%	11.4%	11.4%	12.4%	12.4%	12.2%	12.0%	0.1%
SSRI	AI/AN	10.4%	10.0%	10.6%	10.7%	8.9%	9.4%	9.6%	9.0%	9.1%	8.7%	-1.7%
	Asian	8.6%	9.4%	9.3%	10.0%	9.2%	9.1%	10.0%	9.4%	9.4%	9.5%	0.9%
	Black	12.0%	11.9%	12.0%	12.1%	11.0%	11.1%	11.1%	10.7%	10.3%	10.4%	-1.6%
	NH/OPI	10.1%	9.7%	10.2%	10.8%	9.9%	9.7%	9.9%	9.5%	9.1%	9.1%	-1.0%
	Unknown	8.4%	8.4%	8.6%	9.0%	8.1%	8.0%	7.9%	7.8%	7.7%	7.3%	-1.1%
	White	9.8%	9.4%	9.9%	10.2%	9.0%	8.9%	9.0%	8.5%	8.3%	8.1%	-1.7%
SNRI	AI/AN	2.3%	2.1%	2.2%	2.7%	2.7%	2.9%	4.2%	4.2%	4.5%	4.5%	2.2%
	Asian	1.3%	1.3%	1.5%	2.0%	2.4%	2.6%	3.5%	4.2%	3.9%	4.1%	2.8%
	Black	1.6%	1.7%	1.9%	2.1%	2.3%	2.5%	3.6%	4.1%	4.3%	4.4%	2.8%
	NH/OPI	2.1%	1.9%	2.1%	2.4%	2.4%	2.5%	3.6%	4.1%	4.2%	4.2%	2.1%
	Unknown	1.5%	1.6%	1.7%	1.9%	2.0%	2.1%	2.9%	3.5%	3.7%	3.6%	2.1%
	White	2.5%	2.4%	2.6%	2.8%	2.9%	2.9%	4.0%	4.6%	4.6%	4.6%	2.1%
Atypical Antipsychotic	AI/AN	4.3%	3.5%	2.9%	2.6%	2.5%	2.4%	2.6%	2.2%	2.4%	2.8%	-1.5%
	Asian	3.0%	3.4%	2.6%	2.2%	2.1%	2.2%	2.3%	2.5%	3.0%	3.1%	0.1%
	Black	4.6%	4.1%	3.4%	3.0%	2.8%	2.8%	2.7%	2.7%	2.8%	2.9%	-1.7%
	NH/OPI	4.3%	3.7%	2.9%	2.7%	2.4%	2.2%	2.2%	2.3%	2.5%	2.5%	-1.8%
	Unknown	2.8%	2.7%	2.1%	1.9%	1.8%	1.7%	1.7%	1.7%	2.0%	2.0%	-0.8%
	White	4.5%	3.9%	3.3%	2.9%	2.6%	2.5%	2.4%	2.4%	2.5%	2.5%	-2.0%
Tricyclic Antidepressant	AI/AN	2.1%	2.1%	1.7%	1.5%	1.6%	1.9%	1.8%	1.5%	1.4%	1.4%	-0.7%
	Asian	1.7%	1.6%	1.8%	1.5%	1.4%	1.2%	1.2%	1.5%	1.5%	1.4%	-0.3%
	Black	2.1%	2.0%	1.9%	1.8%	1.8%	1.7%	1.8%	1.6%	1.5%	1.5%	-0.6%

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
	NH/OPI	2.0%	1.5%	1.6%	1.7%	1.4%	1.8%	1.4%	1.4%	1.6%	1.3%	-0.7%
	Unknown	1.3%	1.2%	1.2%	1.2%	1.2%	1.3%	1.2%	1.2%	1.1%	1.1%	-0.2%
	White	1.8%	1.7%	1.6%	1.6%	1.6%	1.6%	1.5%	1.4%	1.3%	1.3%	-0.5%
Mirtazapine	AI/AN	2.4%	2.5%	2.5%	2.5%	2.2%	2.5%	2.8%	2.6%	2.6%	2.4%	0.0%
	Asian	2.0%	2.3%	2.3%	2.7%	2.1%	2.5%	2.5%	2.7%	2.5%	2.6%	0.6%
	Black	3.4%	3.6%	3.6%	3.5%	3.4%	3.6%	3.7%	3.4%	3.3%	3.3%	-0.1%
	NH/OPI	2.6%	2.4%	2.7%	2.6%	2.4%	2.7%	2.7%	2.8%	2.5%	2.6%	0.0%
	Unknown	2.2%	2.1%	2.1%	2.2%	2.1%	2.1%	2.3%	2.1%	2.2%	2.2%	0.0%
	White	2.7%	2.8%	2.8%	2.7%	2.7%	2.7%	2.8%	2.7%	2.6%	2.5%	-0.2%
Prazosin	AI/AN	3.5%	4.5%	4.5%	4.8%	5.0%	5.2%	5.0%	5.0%	4.9%	4.6%	1.1%
	Asian	2.5%	3.4%	3.5%	4.4%	4.5%	5.0%	5.2%	5.3%	5.3%	5.1%	2.6%
	Black	2.9%	3.5%	4.0%	4.5%	4.8%	5.4%	5.7%	5.7%	5.7%	5.3%	2.4%
	NH/OPI	3.1%	3.9%	4.6%	4.6%	5.1%	5.1%	5.2%	5.5%	4.9%	4.8%	1.7%
	Unknown	2.3%	2.7%	3.1%	3.7%	3.7%	3.9%	4.1%	4.2%	4.1%	3.8%	1.5%
	White	3.0%	3.4%	3.7%	4.2%	4.3%	4.5%	4.5%	4.4%	4.3%	3.8%	0.8%
Trazodone	AI/AN	6.0%	5.6%	5.7%	5.8%	5.5%	5.8%	5.8%	5.4%	5.5%	5.3%	-0.7%
	Asian	4.2%	4.4%	4.9%	4.9%	5.4%	5.4%	5.2%	5.6%	5.4%	5.2%	1.0%
	Black	8.0%	8.1%	7.7%	7.6%	7.5%	7.7%	7.4%	7.1%	6.6%	6.7%	-1.3%
	NH/OPI	6.0%	5.7%	5.4%	6.3%	5.6%	5.9%	5.2%	5.3%	4.8%	5.1%	-0.9%
	Unknown	4.5%	4.7%	4.6%	4.7%	4.6%	4.9%	4.7%	4.5%	4.5%	4.4%	-0.1%
	White	5.4%	5.5%	5.3%	5.3%	5.3%	5.4%	5.4%	5.2%	4.9%	4.8%	-0.6%
Non-Benzodiazepine Hypnotics	AI/AN	2.5%	3.1%	2.9%	3.0%	2.3%	2.3%	2.2%	1.6%	1.5%	1.4%	-1.1%
	Asian	2.5%	2.7%	2.5%	3.1%	2.9%	2.9%	2.8%	2.3%	2.1%	1.9%	-0.6%
	Black	2.0%	2.2%	2.3%	2.4%	2.0%	1.9%	1.7%	1.5%	1.3%	1.2%	-0.8%
	NH/OPI	2.4%	3.1%	3.0%	2.8%	2.8%	2.5%	2.2%	2.0%	1.8%	1.7%	-0.7%
	Unknown	2.2%	2.3%	2.3%	2.4%	1.9%	1.9%	1.6%	1.3%	1.3%	1.1%	-1.1%
	White	2.9%	3.0%	2.9%	2.8%	2.4%	2.2%	2.0%	1.8%	1.6%	1.4%	-1.5%

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
Benzodiazepines	AI/AN	5.2%	4.9%	5.1%	4.9%	4.3%	3.9%	3.2%	2.7%	2.2%	2.0%	-3.2%
	Asian	4.1%	4.1%	5.3%	4.3%	4.2%	3.7%	3.1%	2.9%	2.4%	2.2%	-1.9%
	Black	3.3%	3.4%	3.3%	3.1%	2.8%	2.5%	2.1%	1.7%	1.4%	1.3%	-2.0%
	NH/OPI	4.8%	4.7%	4.8%	4.7%	3.8%	3.7%	2.8%	2.5%	1.9%	1.8%	-3.0%
	Unknown	4.2%	4.4%	4.2%	3.9%	3.7%	3.3%	2.8%	2.3%	2.0%	1.5%	-2.7%
	White	5.6%	5.6%	5.4%	5.2%	4.8%	4.2%	3.6%	3.0%	2.6%	2.3%	-3.3%

*Abbreviations.* AI/AN, American Indian or Alaska Native; NH/OPI, Native Hawaiian or Other Pacific Islander; PTSD, Posttraumatic Stress Disorder; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective-serotonin reuptake inhibitor.

Supplementary Table 7. *Ethnicity Differences in New Prescriptions Among Veterans Diagnosed with PTSD by Year (2009-2018)*

		2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	Absolute Change
SSRI or SNRI	H/L	12.6%	12.9%	13.3%	13.6%	13.0%	13.1%	13.9%	14.4%	14.3%	14.1%	1.5%
	Not H/L	12.0%	11.6%	12.2%	12.7%	11.5%	11.6%	12.6%	12.6%	12.5%	12.4%	0.4%
SSRI	H/L	11.2%	11.3%	11.5%	11.7%	10.7%	10.8%	10.8%	10.7%	10.3%	10.1%	-1.1%
	Not H/L	10.1%	9.8%	10.2%	10.5%	9.3%	9.2%	9.3%	8.8%	8.6%	8.5%	-1.6%
SNRI	H/L	1.7%	2.0%	2.2%	2.3%	2.7%	2.8%	3.8%	4.4%	4.7%	4.7%	3.0%
	Not H/L	2.3%	2.2%	2.4%	2.7%	2.7%	2.8%	3.9%	4.4%	4.5%	4.5%	2.2%
Atypical Antipsychotic	H/L	4.4%	3.8%	3.1%	2.7%	2.6%	2.5%	2.3%	2.5%	2.6%	2.7%	-1.7%
	Not H/L	4.4%	3.9%	3.2%	2.9%	2.6%	2.6%	2.4%	2.5%	2.6%	2.6%	-1.8%
Tricyclic Antidepressant	H/L	1.8%	1.5%	1.6%	1.5%	1.5%	1.6%	1.6%	1.4%	1.5%	1.5%	-0.3%
	Not H/L	1.9%	1.8%	1.6%	1.6%	1.6%	1.6%	1.5%	1.4%	1.4%	1.3%	-0.6%
Mirtazapine	H/L	2.6%	2.6%	2.9%	2.7%	2.8%	2.9%	3.0%	3.0%	2.9%	2.7%	0.1%
	Not H/L	2.8%	2.9%	2.9%	2.9%	2.8%	2.9%	2.9%	2.8%	2.7%	2.7%	-0.1%
Prazosin	H/L	3.3%	3.9%	4.4%	4.8%	5.3%	5.5%	5.7%	5.6%	5.6%	5.1%	1.8%
	Not H/L	2.9%	3.4%	3.7%	4.2%	4.3%	4.6%	4.7%	4.6%	4.5%	4.1%	1.2%
Trazodone	H/L	5.9%	6.2%	6.3%	6.4%	6.3%	6.5%	6.4%	6.3%	6.0%	5.9%	0.0%
	Not H/L	5.9%	5.9%	5.7%	5.7%	5.6%	5.8%	5.7%	5.5%	5.2%	5.2%	-0.7%
Non-Benzodiazepine Hypnotics	H/L	2.4%	2.9%	3.0%	3.2%	2.7%	2.5%	2.2%	2.0%	1.8%	1.7%	-0.7%
	Not H/L	2.7%	2.8%	2.8%	2.7%	2.3%	2.1%	1.9%	1.7%	1.5%	1.3%	-1.4%
Benzodiazepines	H/L	5.1%	5.2%	4.9%	4.8%	4.4%	4.0%	3.1%	2.7%	2.2%	1.9%	-3.2%
	Not H/L	5.1%	5.1%	5.0%	4.7%	4.3%	3.8%	3.3%	2.7%	2.3%	2.0%	-3.1%

*Abbreviations.* H/L, Hispanic or Latino; PTSD, Posttraumatic Stress Disorder; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective-serotonin reuptake inhibitor.

Supplementary Table 8. *Service Era Differences in New Prescriptions Among Veterans Diagnosed with PTSD by Year (2009-2018)*

		2009	2010	2011	2013	2014	2015	2016	2017	2018	Absolute Change
SSRI or SNRI	OEF/OIF/OND	13.8%	14.0%	14.6%	15.0%	14.4%	14.8%	15.8%	15.9%	15.7%	1.9%
	Not OEF/OIF/OND	11.6%	11.0%	11.6%	12.0%	10.7%	10.5%	11.3%	11.3%	11.2%	-0.4%
SSRI	OEF/OIF/OND	12.0%	12.1%	12.4%	12.6%	11.8%	12.1%	12.2%	11.8%	11.5%	-0.5%
	Not OEF/OIF/OND	9.7%	9.3%	9.7%	9.9%	8.5%	8.3%	8.3%	7.7%	7.5%	-2.2%
SNRI	OEF/OIF/OND	2.3%	2.5%	2.7%	3.0%	3.2%	3.4%	4.5%	5.0%	5.1%	2.8%
	Not OEF/OIF/OND	2.2%	2.1%	2.3%	2.5%	2.5%	2.6%	3.6%	4.2%	4.2%	2.0%
Atypical Antipsychotic	OEF/OIF/OND	4.8%	4.6%	3.8%	3.5%	3.2%	3.2%	3.1%	3.1%	3.2%	-1.6%
	Not OEF/OIF/OND	4.3%	3.7%	3.0%	2.6%	2.4%	2.3%	2.1%	2.2%	2.3%	-2.0%
Tricyclic Antidepressant	OEF/OIF/OND	2.0%	2.0%	1.9%	1.8%	1.9%	1.9%	1.8%	1.7%	1.7%	-0.3%
	Not OEF/OIF/OND	1.8%	1.7%	1.6%	1.5%	1.5%	1.5%	1.4%	1.3%	1.2%	-0.6%
Mirtazapine	OEF/OIF/OND	2.9%	2.9%	3.0%	3.1%	3.0%	3.2%	3.3%	3.1%	2.9%	0.0%
	Not OEF/OIF/OND	2.8%	2.8%	2.8%	2.8%	2.7%	2.7%	2.8%	2.7%	2.6%	-0.2%
Prazosin	OEF/OIF/OND	3.9%	4.8%	5.2%	5.8%	6.1%	6.5%	6.7%	6.6%	6.4%	2.5%
	Not OEF/OIF/OND	2.7%	3.1%	3.3%	3.8%	3.8%	4.0%	4.0%	3.9%	3.8%	1.1%
Trazodone	OEF/OIF/OND	6.2%	6.5%	6.4%	6.6%	6.5%	6.8%	6.6%	6.4%	6.1%	-0.1%
	Not OEF/OIF/OND	5.8%	5.7%	5.5%	5.5%	5.4%	5.5%	5.4%	5.2%	4.9%	-0.9%
Non-Benzodiazepine Hypnotics	OEF/OIF/OND	2.9%	3.5%	3.6%	3.5%	3.0%	2.8%	2.5%	2.2%	2.0%	-0.9%
	Not OEF/OIF/OND	2.6%	2.6%	2.6%	2.5%	2.1%	1.9%	1.7%	1.5%	1.3%	-1.3%
Benzodiazepines	OEF/OIF/OND	4.4%	4.8%	4.9%	4.7%	4.3%	3.8%	3.2%	2.6%	2.2%	-2.2%
	Not OEF/OIF/OND	5.2%	5.1%	5.0%	4.7%	4.3%	3.8%	3.2%	2.7%	2.4%	-2.7%

*Abbreviations.* OEF/OIF/OND, Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn; PTSD, Posttraumatic Stress Disorder; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective-serotonin reuptake inhibitor.